Clinical Effect of Lenvatinib Re-Administration after Transcatheter Arterial Chemoembolization in Patients with Intermediate Stage Hepatocellular Carcinoma.

Autor: Mawatari, Seiichi, Tamai, Tsutomu, Kumagai, Kotaro, Saisyoji, Akiko, Muromachi, Kaori, Toyodome, Ai, Taniyama, Ohki, Sakae, Haruka, Ijuin, Sho, Tabu, Kazuaki, Oda, Kohei, Hiramine, Yasunari, Moriuchi, Akihiro, Sakurai, Kazuhiro, Kanmura, Shuji, Ido, Akio
Předmět:
Zdroj: Cancers; 12/15/2022, Vol. 14 Issue 24, p6139, 12p
Abstrakt: Simple Summary: We investigated the prognosis of intermediate-stage hepatocellular carcinoma (HCC) patients who received lenvatinib (LEN) until unacceptable adverse events or progressive disease, followed by transcatheter arterial chemoembolization (TACE) on demand. The overall survival (OS) in patients for whom LEN was re-administered after TACE (TACE-LEN) was significantly longer in comparison to patients who received other therapies, such as only TACE, other drugs after TACE, or other drugs without TACE. TACE-LEN was the most associated with OS in the Cox proportional hazard analysis. In intermediate-stage HCC patients who can tolerate LEN without discontinuation due to AEs, TACE-LEN may prolong the prognosis. The present study clarified the prognosis of intermediate-stage hepatocellular carcinoma (HCC) patients who received lenvatinib (LEN) followed by transcatheter arterial chemoembolization (TACE) on demand. We retrospectively evaluated 88 intermediate-stage HCC patients who received LEN. The median age was 74 (range: 47–92) years old, 67 patients were male, and 82 were classified as Child-Pugh A. LEN was administered until disease progression or discontinuation due to adverse events (AEs). The mean duration of LEN treatment was 7.0 months. The response and disease control rates were 51.1% and 89.8%, respectively. The median progression-free survival and overall survival (OS) after the initiation of LEN were 6.8 months and 29.9 months, respectively. The OS in patients for whom LEN was re-administered after TACE (TACE-LEN) was better than that in patients who received other therapies (e.g., only TACE, TACE-other therapy, or only other therapy) even with propensity score matching (p = 0.008). A Cox proportional hazard analysis showed that TACE-LEN was most strongly associated with the OS (hazard ratio: 0.083, 95% confidence interval: 0.019–0.362, p = 0.001). LEN was administered for approximately 11.1 months after TACE. In intermediate-stage HCC patients who can tolerate LEN without discontinuation due to AEs, TACE-LEN may prolong the prognosis. [ABSTRACT FROM AUTHOR]
Databáze: Complementary Index
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje